Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus bevacizumab for persistent, recurrent, or metastatic cervical cancer
ChiCTR2100047015Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and bevacizumab in Cervical Cancer (CC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Objective response rate and Safety and tolerability. Started May 2021; status: recruiting.
02
Drugs
tislelizumabbevacizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2100047015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047015.